Bates B A, Detterbeck F C, Bernard S A, Qaqish B F, Tepper J E
Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill 27599-7512, USA.
J Clin Oncol. 1996 Jan;14(1):156-63. doi: 10.1200/JCO.1996.14.1.156.
A prospective study was performed to determine the outcome of patients with esophageal cancer who received preoperative radiation therapy and chemotherapy followed by esophagectomy, and to determine the role of preresection esophagogastroduodenoscopy (EGD) in predicting the patients in whom surgery could possibly be omitted, and the impact of surgery on survival.
Thirty-five patients with localized carcinoma of the esophagus received concurrent external-beam radiotherapy and chemotherapy followed by esophagectomy. Patients received 45 Gy in 25 fractions. Chemotherapy consisted of continuous infusion fluorouracil (5-FU; 1,000 mg/m2/d) on days 1 through 4 and 29 through 32 and cisplatin (100 mg/m2) on day 1. Patients underwent an Ivor-Lewis esophagectomy 18 to 33 days after completion of radiotherapy.
Eighty percent of the patients had squamous cell carcinoma and 20% had adenocarcinoma. In addition, 51% had a pathologic complete response (CR). Twenty-two of the 35 underwent a preresection EGD before resection. Seventeen of the 22 (77%) had negative pathology from the preresection EGD, but seven of the 17 (41%) had residual tumor at surgery. The median survival and disease-free survival rates for all patients were 25.8 months and 32.8 months, respectively. Eighteen patients (51%) had no tumor at resection. The median survival for these patients was 36.8 months; the median disease-free survival time has not been reached. The median survival and disease-free survival rate for the patients with residual tumor in the surgical specimen were 12.9 months and 10.8 months, respectively.
Preresection EGD is not reliable for determining the presence of residual disease or the patients in whom surgery could be omitted. Twenty-five percent of the patients with residual tumor in the resected surgical specimen were long-term survivors; this suggests a benefit from esophagectomy after concurrent radiotherapy and chemotherapy.
进行一项前瞻性研究,以确定接受术前放疗和化疗后行食管切除术的食管癌患者的预后,并确定术前食管胃十二指肠镜检查(EGD)在预测可能无需手术的患者中的作用以及手术对生存的影响。
35例局限性食管癌患者接受同步外照射放疗和化疗,随后行食管切除术。患者在25次分割中接受45 Gy照射。化疗包括在第1至4天和第29至32天持续输注氟尿嘧啶(5-FU;1000 mg/m²/天)以及在第1天给予顺铂(100 mg/m²)。患者在放疗完成后18至33天行Ivor-Lewis食管切除术。
80%的患者为鳞状细胞癌,20%为腺癌。此外,51%的患者达到病理完全缓解(CR)。35例患者中有22例在切除术前接受了EGD检查。22例中的17例(77%)术前EGD病理检查为阴性,但这17例中的7例(41%)在手术时有残留肿瘤。所有患者的中位生存期和无病生存期分别为25.8个月和32.8个月。18例患者(51%)切除时无肿瘤。这些患者的中位生存期为36.8个月;中位无病生存时间尚未达到。手术标本中有残留肿瘤的患者的中位生存期和无病生存率分别为12.9个月和10.8个月。
术前EGD对于确定残留疾病的存在或预测可能无需手术的患者并不可靠。手术切除标本中有残留肿瘤的患者中有25%为长期生存者;这表明同步放化疗后行食管切除术有获益。